Related Experiment Video
Updated: Mar 8, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
3.6K
Opioid system in L-DOPA-induced dyskinesia
1Transgenics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Building 35, Room 1A112, MSC 3707, 35 Convent Drive, Bethesda, MD 20892-3707 USA.
Translational Neurodegeneration
|January 21, 2017
Summary
L-3,4-Dihydroxyphenylalanine (L-DOPA)-induced dyskinesia, a complication of Parkinson's disease treatment, involves abnormal opioid signaling in the brain. Investigating this opioid pathway may reveal new therapeutic targets for Parkinson's disease patients.
Area of Science:
- Neuroscience
- Pharmacology
- Neurology
Background:
- L-3,4-Dihydroxyphenylalanine (L-DOPA) is a primary treatment for Parkinson's disease (PD).
- L-DOPA-induced dyskinesia (LID) is a significant and debilitating side effect of PD treatment.
- Altered endogenous opioid signaling in the basal ganglia is a known characteristic of LID.
Purpose of the Study:
- To review the current understanding of opioid signal transduction in the basal ganglia.
- To elucidate the contribution of malfunctioning opioid signaling to the pathophysiology of LID.
- To explore the potential of the opioid system as a therapeutic target for LID.
Main Methods:
- Literature review of studies on opioid signaling in the basal ganglia.
- Analysis of the role of opioid pathways in the development of L-DOPA-induced dyskinesia.
- Synthesis of current knowledge regarding the pathophysiology of LID.
Main Results:
- Aberrant opioid signal transduction pathways are consistently observed in LID.
- Opioid receptors represent a potential target for mitigating L-DOPA-induced dyskinesia.
- The precise role of altered opioid activity in LID remains an active area of research.
Conclusions:
- Dysfunctional opioid signaling in the basal ganglia is implicated in the pathophysiology of LID.
- Targeting the opioid system offers a promising avenue for developing novel therapeutic strategies for PD patients experiencing LID.
- Further research into the opioid system's role in LID is crucial for improving treatment outcomes in Parkinson's disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
787
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
787
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.6K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.6K
01:22Opioid Receptors: Overview
5.7K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
5.7K
01:15Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
01:29Drugs Affecting Neurotransmitter Synthesis
2.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.4K